I hope that you have a good start to 2023. At o2h discovery we kicked off the year with a busy fun packed schedule at various events at the JPM Healthcare conference week in San Francisco, USA. Always a great way to kick to get the biotech juices flowing again.
I hope you enjoy reading this update and we look forward to connecting and supporting you with discovery programmes this year. We appreciate all the support and business from our friends, collaborators and broader biotech community that we receive throughout the year. We love what we do, and what we do is only possible thanks to all the advice, support and kindness that we receive.
We look forward to an amazing 2023!
Best wishes,
the o2h discovery team
|
|
the o2h kickstarter competition 2.0
|
|
|
After receiving an overwhelming response from the first competition, we are now launching the second edition of the o2h kickstarter competition, specifically focused on Australian biotech startups. The programme aims to extend o2h discovery’s small molecule and medicinal chemistry research expertise to seed early stage Aus biotech companies who have innovative ideas in drug science and are planning to push it forward to the next milestones. Read more
|
|
winners of the first edition of the o2h kickstarter competition
|
|
|
In our first kickstarter competition we had more than 30 companies apply from across the globe, and six of these made it to the winners list. We launched the o2h kickstarter competition with a vision to give a discovery boost to the early-stage Biotech companies. The rationale was to support the biotech startups with limited funding by providing enabling chemistry services at the beginning of their growth journey. Read more
|
|
|
building the discovery base...
|
|
|
|
You will see further updates this year from o2h discovery on the growth of service offerings and depth we are building behind our PROTAC experience supporting Protein Degradation programmes and the technical capability that we have and are developing around the synthesis ionic phospholipids for developing of novel LNP’s (Lipid Nanoparticles).
Below are some of the capabilities that we have added to o2h discovery recently outside of these two core areas of technical differentiation that we have been developing...
|
|
|
Solid-phase Peptide Synthesis
o2h discovery has peptide synthesis, purification and characterisation capabilities. We synthesise peptides of 2-40 amino acids using the latest Fmoc solid-phase technology from mg to gram scale, and purify our products using HPLC. o2h discovery recently purchased a Biotage SYRO I, fully automated multi-channel peptide synthesiser.
To know more about our peptide synthesis service offering, please reach out to Claudio at discovery@o2h.com.
|
|
|
Further investment in our NMR capacity
o2h discovery has purchased an additional new two-channel 400 MHz NMR spectrometer to provide a faster turnaround times and to ensure we are deploying the latest analytical support to clients. NMR spectroscopy is important in the drug discovery and development process. It aids in the discovery of hits, their validation, and further advancement to lead optimization.
|
|
|
|
o2h biology has the infrastructure and expertise to conduct a wide range of biochemical, biophysical, and cellular assays against multiple target classes. To augment these services, we have incorporated Surface Plasmon Resonance (SPR) to our portfolio using state-of-the-art, Biacore T200 system.
|
|
|
The Biacore T200 provides real-time, label-free, affinity and kinetic analysis for various types of biomolecular interactions with high sensitivity and accuracy. Our medicinal chemists have built a proprietary fragment-based drug discovery (FBDD) platform in conjunction with academic computational chemists.
|
|
|
The small molecule fragments are diverse and amenable to further diversification, offering tractable starting points for a wide variety of targets. With Biacore T200 we can efficiently screen our proprietary fragment library and small molecules for their biophysical binding properties, thereby measuring compounds for their association (Kon), dissociation rates (Koff) and dissociation constant (KD). Our scientists can support you with different immobilisation techniques, measure target responsiveness and establish reliable methods for biomolecular interactions, and facilitate subsequent medicinal chemistry driven structure-activity-relationship and development. Reach out to the team at discovery@o2h.com
|
|
|
o2h discovery out and about...
|
|
|
|
Genesis 2022
o2h discovery made its presence at Genesis 2022 which took place in London during 5th -8th Dec 2022. This year the theme was “Maximising Returns from Life Science Innovation” and aimed to bring together key opinion leaders, investors and innovators from across the sector to share insight, debate key trends and generate deals.
|
|
|
|
Claudio Dagostin, Director of Business Development represented o2h discovery in this event. Read more
|
|
|
CPHI, India 2022
o2h discovery made its presence at CPHI & PMEC, India held during 29th Nov - 1st Dec 2022. CPHI organizes a massive and widespread series of global pharmaceutical events, where they bring together more than 500,000 powerful and reputed pharma players, API manufacturers, pharmaceutical excipients and analysis solution providers for the pharmaceutical chemical and biotech fields. Hemal, Head of Chemistry represented o2h discovery in this event.
|
|
Biotech Bootcamp
|
|
|
o2h co-work labs, a business unit of o2h group had a great time hosting yet another free flowing edition of our signature influencer biotech bootcamp. The event was spread over two days covering a dozen influencers sharing live grassroots experiences and who have demonstrated a serious stake in shaping the future of biotech. We had candid conversation around the investment landscape, creativity, strategy/team development, customers/investor, deals/exits, technology, and how to build a world leading ecosystem. Read more
|
|
Biotech Bikers
|
|
|
|
We enjoyed hosting another addition of our Biotech Bikers late last year, catching a piece of Autumn sun (and rain!), and we toured the local biotech parks in Cambridge. We started and finished at our UK global headquarters in Cambridge, UK (where our part of the discovery biology team is based). Connecting the Cambridge Biotech community through sport is one of our most favoured events of the year. As the weather starts to improve we are planning our next Biotech Bikers for April 2023…Be ready.
|
|
|
|
